Demographic Variations in Immune Checkpoint Inhibitor Adverse Events: A Real-World Study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have caused a paradigm shift in cancer therapy, but the resultant immune activation also precipitates autoimmune toxicities termed immune-related adverse events (irAEs). However, system-specific analyses of irAEs remain limited, particularly their variation with body mass index (BMI), race, sex, age, and type of ICI.

Methods

A retrospective analysis was conducted on 244 patients who developed irAEs after receiving ICI. Among the study population, 58% were female; the racial and ethnic distribution was 84% White, 13% Hispanic, 2% African American, and 1% Asian; and the age breakdown was 23% under 65 years, 38% between 65 and 79 years, and 39% over 80 years. Univariate analysis was performed employing the Chi-square test. Multivar

SUBMITTER: Shambhavi S 

PROVIDER: S-EPMC12479073 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature